Although immunotherapy has brought a revolutionary breakthrough in cancer treatment, the use of CTLA4 and PD1 blockers can lead to an over-activation of the immune system, resulting in increased intestinal permeability and loss of intestinal barrier integrity, which can cause systemic inflammation and immune-related adverse events (irAEs). The gene discussed is CTLA4; the disease is cancer.